Genmab A/S (NASDAQ:GMAB) Receives $45.20 Average PT from Brokerages

Genmab A/S (NASDAQ:GMAB) has earned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $45.20.

A number of equities research analysts have commented on the company. BTIG Research raised their price objective on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Truist Financial decreased their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Redburn Atlantic began coverage on Genmab A/S in a report on Tuesday. They set a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Friday, September 20th.

Genmab A/S Trading Up 0.7 %

Shares of GMAB opened at $23.59 on Friday. The business’s 50-day moving average price is $26.45 and its 200 day moving average price is $27.49. The stock has a market capitalization of $15.60 billion, a P/E ratio of 19.67, a P/E/G ratio of 0.73 and a beta of 0.98. Genmab A/S has a 1-year low of $23.24 and a 1-year high of $35.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. On average, research analysts predict that Genmab A/S will post 1.27 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its holdings in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the last quarter. GAMMA Investing LLC increased its position in Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after buying an additional 749 shares during the period. Allspring Global Investments Holdings LLC bought a new position in Genmab A/S in the 1st quarter worth approximately $43,000. Barometer Capital Management Inc. bought a new position in Genmab A/S in the 4th quarter worth approximately $121,000. Finally, Headlands Technologies LLC increased its position in Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after buying an additional 4,853 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.